Breakthrough T1D congratulates non-profit pharmaceutical company Civica on the launch of its first low-cost, long-acting insulin. Beginning Jan. 1, 2026, Civica insulin glargine in pre-filled pens will be available in the United States for no more than $55 for a box of five pens. Breakthrough T1D is one of more than 25 philanthropic partner organizations who, along with the states of California and Virginia, joined together to support Civica’s development of three commonly prescribed insulins.
“For people with type 1 diabetes, insulin is a lifesaving drug. Too often, the cost of insulin is a barrier that causes people to make difficult decisions between their medication and other necessities,” said Aaron J. Kowalski, Ph.D., Breakthrough T1D CEO. “The availability of Civica’s insulin glargine is a significant next step in ensuring that insulin is accessible and affordable for people with type 1 diabetes and all those who need it, regardless of their insurance status. Breakthrough T1D is proud to partner with Civica as they continue their efforts to develop affordable insulins for the diabetes community.”
Breakthrough T1D has supported Civica since 2022 when the organization established its project to develop low-cost biosimilar insulins.
